EGFR and non-small cell lung carcinoma: Interestingly, Hirano et al. suggested that OSI has potent efficacy against NSCLC harboring EGFR 19 deletion and L858R mutation, as well as those harboring exon 20 insertion mutations, suggesting a wide therapeutic window of OSI in NSCLC38.